These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 16981846)

  • 21. Report on financing the new model of family medicine.
    Spann SJ;
    Ann Fam Med; 2004 Dec; 2 Suppl 3(Suppl 3):S1-21. PubMed ID: 15654084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
    Smith DG; Cerulli A; Frech FH
    Clin Ther; 2005 Jun; 27(6):951-9. PubMed ID: 16117995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cost of asthma therapy in relation to severity. An empirical study].
    Graf von der Schulenburg JM; Greiner W; Molitor S; Kielhorn A
    Med Klin (Munich); 1996 Oct; 91(10):670-6. PubMed ID: 9019647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of combinatorial pharmacogenomic guidance in treating psychiatric disorders.
    Benitez J; Cool CL; Scotti DJ
    Per Med; 2018 Nov; 15(6):481-494. PubMed ID: 30256179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing the cost-effectiveness of pharmacogenomics.
    Veenstra DL; Higashi MK; Phillips KA
    AAPS PharmSci; 2000; 2(3):E29. PubMed ID: 11741245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacoeconomics of asthma treatment.
    Cleland J; Thomas M; Price D
    Expert Opin Pharmacother; 2003 Mar; 4(3):311-8. PubMed ID: 12614183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer patients acceptance, understanding, and willingness-to-pay for pharmacogenomic testing.
    Cuffe S; Hon H; Qiu X; Tobros K; Wong CK; De Souza B; McFarlane G; Masroor S; Azad AK; Hasani E; Rozanec N; Leighl N; Alibhai S; Xu W; Issa AM; Liu G
    Pharmacogenet Genomics; 2014 Jul; 24(7):348-55. PubMed ID: 24911662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Asthma pharmacogenetic study using finite mixture models to handle drug-response heterogeneity.
    York TP; Vargas-Irwin C; Anderson WH; van den Oord EJ
    Pharmacogenomics; 2009 May; 10(5):753-67. PubMed ID: 19450127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world clinical effectiveness, regulatory transparency and payer coverage: three ingredients for translating pharmacogenomics into clinical practice.
    Frueh FW
    Pharmacogenomics; 2010 May; 11(5):657-60. PubMed ID: 20415556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 4th Annual Pharmacogenomics and Medicine Lectures.
    Oestreicher P
    Pharmacogenomics; 2001 Aug; 2(3):291-6. PubMed ID: 11939134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics.
    Phillips KA; Veenstra D; Van Bebber S; Sakowski J
    Pharmacogenomics; 2003 May; 4(3):231-9. PubMed ID: 12718713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The value of routine pharmacogenomic screening-Are we there yet? A perspective on the costs and benefits of routine screening-shouldn't everyone have this done?
    Veenstra DL
    Clin Pharmacol Ther; 2016 Feb; 99(2):164-6. PubMed ID: 26565561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenomics: the promise of personalized medicine for CNS disorders.
    de Leon J
    Neuropsychopharmacology; 2009 Jan; 34(1):159-72. PubMed ID: 18800072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing the use of retrospective databases in conducting economic evaluations of drugs: the case of asthma.
    Berggren F
    Pharmacoeconomics; 2004; 22(12):771-91. PubMed ID: 15294011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluation of pharmacogenomics: a value-based approach to pragmatic decision making in the face of complexity.
    Snyder SR; Mitropoulou C; Patrinos GP; Williams MS
    Public Health Genomics; 2014; 17(5-6):256-64. PubMed ID: 25278172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of pharmacogenomics in improving the management of asthma.
    Kazani S; Wechsler ME; Israel E
    J Allergy Clin Immunol; 2010 Feb; 125(2):295-302; quiz 303-4. PubMed ID: 20159237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenomics of asthma.
    Pahl A; Benediktus E; Chialda L
    Curr Pharm Des; 2006; 12(25):3195-206. PubMed ID: 17020528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic review of pharmacoeconomic studies of pharmacogenomic tests.
    Beaulieu M; de Denus S; Lachaine J
    Pharmacogenomics; 2010 Nov; 11(11):1573-90. PubMed ID: 21121811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenomic test that predicts response to β
    Wu AC; Gay C; Rett MD; Fuhlbrigge AL
    Per Med; 2015 Nov; 12(6):574-584. PubMed ID: 29750604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NAVAGATE: a rubric to move from pharmacogenomics science to pharmacogenomics practice.
    Roederer MW
    Pharmacogenomics; 2012 Aug; 13(11):1307-13. PubMed ID: 22920399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.